The de novo diagnosis of systemic lupus erythematosus and lupus nephritis during pregnancy Tapan Patel, MD, Andrew Fenves, MD, and Gates Colbert, MD S ystemic lupus erythematosus (SLE) is a multisystem autoimmune connective tissue disorder. SLE has marked female predominance, with a 9:1 female-to-male ratio, and generally aff ects young women of childbearing age. Some women have monthly worsening of symptoms with onset of menses (1) . Although some evidence indicates that the increased female prevalence is due to estrogen, it is likely that complex interactions of multiple hormones, including estrogen, prolactin, dehydroepiandrosterone, and testosterone, are involved (2) .
Fertility is generally preserved in SLE patients, except when renal function is seriously compromised, the disease is very active, or amenorrhea has been induced by cytotoxic therapy such as cyclophosphamide (3). SLE's eff ects on pregnancy are controversial. . Although some studies found an increase in the number and severity of SLE fl ares during pregnancy (4, 5) , others found no worsening of fl ares (6) (7) (8) .
We report two patients who were fi rst diagnosed with SLE during pregnancy and review the interaction of SLE and pregnancy.
CASE 1
A 22-year-old African American woman, gravida 2, para 1, presented to another hospital at 6 weeks' gestation with diff use joint pain and malar rash. She had no family history of SLE and no past history of miscarriages or blood clot formation. She was found to have positive antinuclear antibodies (ANA) at a titer of 1:2560. Th e patient also had a positive anti-DNA antibody, low complement factors (C3, 84 mg/dL; C4, 9 mg/dL), leukopenia, and anemia on further workup. She was diagnosed with SLE based on clinical features and laboratory fi ndings and was started on oral prednisone 30 mg daily, which was subsequently decreased to 20 mg daily.
At 30 weeks' gestation, she presented to the maternal-fetal medicine clinic at Baylor University Medical Center at Dallas (BUMC) for an ultrasound. At that time she was taking amlodipine 5 mg daily, prednisone 20 mg daily, and ferrous sulfate 325 mg three times daily and had no known drug allergies. She was found to be hypertensive with a blood pressure of 163/99 mm Hg. She also complained of a mild headache and "dots" in her vision. She denied uterine contractions, vaginal bleeding, or leakage of fl uid. Her past medical history was signifi cant for preexisting hypertension. She developed chorioamnionitis and preeclampsia during a previous pregnancy and required a cesarean section at 39 weeks. Th e patient was admitted to BUMC with possible preeclampsia superimposed on chronic hypertension.
At admission, urinalysis showed +2 dipstick protein, 30 to 50 white blood cells per high-power fi eld, and microscopic hematuria. Subsequent 24-hour urine contained 1523 mg of protein. Her serum creatinine was 0.6 mg/dL; blood urea nitrogen (BUN), 5 mg/dL; and uric acid, 3.9 mg/dL. Serologic studies included a rheumatoid factor of 8 IU/mL; rapid plasma reagin, nonreactive; C3, 81.1 mg/dL; C4, 8.4 mg/dL; CH50, 267 units; anti-U1 ribonucleoprotein, positive; anticardiolipin IgG, <10 GPL; anticardiolipin IgM, 10.8 MPL; anti-DNA antibody titer, 1:1280; ANA titer, 1:2560; and anti-cyclic citrullinated protein antibody, negative.
Prednisone was continued at the dose of 20 mg per day. A renal ultrasound showed that the right kidney was of normal size (12.2 cm length) with mild hydronephrosis likely caused by ureteral compression secondary to the gravid uterus. Th e left kidney was slightly enlarged (13.3 cm length). Both kidneys had normal cortical echogenicity and thickness. Urine culture was positive for group beta streptococcus, and the patient was treated with amoxicillin.
Hydralazine 25 mg twice a day was added to the oral amlodipine dose (5 mg per day), and subsequently the amlodipine dose was increased to 10 mg per day. Th e condition of both mother and fetus was relatively stable, and the patient's blood pressure improved. On hospital day 8, the patient was discharged with planned outpatient follow-up by the nephrology and rheumatology services. Her renal function was stable at the time of discharge, with a serum creatinine of 0.6 mg/dL and BUN of 8 mg/dL. Her serum uric acid level was 4.2 mg/dL, and 24-hour urine protein excretion was 803 mg at the time of discharge.
Th e patient returned to BUMC 23 days after discharge with preterm rupture of membranes and underwent cesarean section with delivery of a preterm infant. Her renal function was stable at that time (serum creatinine, 0.7 mg/dL). She did not follow up with nephrology or rheumatology after the second discharge.
CASE 2
A 21-year-old obese (222-pound) nulliparous Caucasian woman was evaluated at 11 weeks' gestation and was found to have a serum creatinine of 0.58 mg/dL and BUN of 8 mg/ dL. Her aspartate aminotransferase, alanine aminotransferase, albumin, and urinalysis were all normal. At 13 weeks' gestation, she developed hypertension with a blood pressure of 155/100 mm Hg. Urinalysis revealed 2+ protein and 10 to 30 red blood cells per high-power fi eld, and her serum creatinine was now 1.38 mg/dL. A 24-hour urine showed a creatinine clearance of 33 mL/min and protein of 3.48 g. A renal sonogram showed that the right kidney was 10.4 cm long and the left kidney, 12.7 cm long. Th e kidneys had normal shape and echogenicity. No hydronephrosis or mass was detected. Her only medications were prenatal vitamins, and she denied use of nonsteroidal antiinfl ammatory drugs. She had lost weight during the fi rst trimester, from 222 to 213 pounds. Her past medical history was signifi cant only for two antenatal urinary tract infections that had resolved with ciprofl oxacin treatment. Th ere was no family history of hypertension or kidney disease. She was referred to a nephrologist because of these problems, and oral methyldopa was started for hypertension.
Th e patient was admitted to BUMC at 23 weeks' gestation for monitoring and bed rest due to the high risk of her pregnancy. On admission, her serum creatinine was further increased at 3.2 mg/dL. Focal segmental glomerulosclerosis and membranous nephropathy were in the diff erential diagnosis for renal failure and proteinuria in this patient. A kidney biopsy performed for diagnosis and potential treatment options showed diff use proliferative lupus nephritis with crescents (class IV) (Figure) . Electron microscopy showed subendothelial, subepithelial, and mesangial deposits. Her ANA titer was 1:640, with reportedly low C3 and C4 complement level from an outside laboratory.
Oral mycophenolate mofetil 500 mg twice a day and oral prednisone 100 mg daily were started. Subsequently, prednisone was tapered to 60 mg daily, and mycophenolate mofetil was increased to 1 g twice a day. Th e patient was also started on oral methyldopa and labetalol. At 25 weeks' gestation, hemodialysis was initiated using a right internal jugular vein-tunneled dialysis catheter. She received daily dialysis treatments for 9 days. Her blood pressure worsened, and at 26 weeks' gestation, she underwent cesarean section to deliver a boy who subsequently died at the age of 9 months of respiratory failure. After delivery, she was switched from methyldopa to oral enalapril for better control of hypertension. She was discharged 8 days after delivery with a serum creatinine of 3.1 mg/dL.
Two weeks after discharge, she remained on prednisone and mycophenolate mofetil. Her serum creatinine remained 3.1 mg/dL, and her BUN was 94 mg/dL. Her blood pressure was 135/82 mm Hg and she weighed 204 pounds, down 45 pounds from her peak weight during pregnancy. Th is large weight loss was due to delivery and the clearance of accumulated fl uid.
Seven weeks after delivery, her serum creatinine was 2.11 mg/dL. Fourteen weeks after delivery, her serum creatinine was 1.68 mg/dL; BUN, 16 mg/dL; and albumin, 3.8 mg/dL. Her hemoglobin was reduced to 8.4 mg/dL and hematocrit was 26.2%. Her anemia was presumed to be due to chronic kidney disease. Erythropoiesis-stimulating agent (ESA) was started after confi rming suffi cient body stores of iron (serum ferritin, 230 ng/mL; serum iron, 65 μg/dL). She weighed 188 pounds and her blood pressure was normal on enalapril 20 mg orally twice a day. She continued oral mycophenolate mofetil 1 g twice a day and was also taking oral hydroxychloroquine 400 mg daily.
At 28 weeks after delivery, her serum creatinine was 1.01 mg/dL; BUN, 17 mg/dL; hemoglobin, 12.4 g/dL; and hematocrit, 37.8%. Her urine protein excretion had fallen, as documented by a spot urine protein-creatinine ratio of 1.94 mg/g. ESA therapy was discontinued.
Two years after delivery, the patient's serum creatinine was 0.8 mg/dL, and her SLE was well controlled on low-dose mycophenolate mofetil and prednisone.
DISCUSSION
In normal healthy women, successful pregnancy depends on adaptation of the maternal immune system that becomes tolerant to fetal antigens of paternal origin. Altered immune regulation induced by pregnancy is manifested mainly at the fetomaternal surface. One of the most important modifi cations during development of autoimmune rheumatic diseases during pregnancy is a Th 1/Th 2 shift. It occurs both at the fetoplacental barrier and in maternal circulation and is driven by physiological increases in progesterone and estrogen during pregnancy (9) . In physiological conditions, it seems that estrogen stimulates both humoral and cellular immune responses (Th 1 and Th 2 cytokines). Interestingly, at higher than physiological concentrations, such as those reached during pregnancy, it seems that estrogen inhibits cell-mediated immune response (Th 1 cytokines), whereas antibody production is induced (Th 2 cytokines). Th e polarization of the Th 2 response may explain why the condition of the patient aff ected by rheumatoid arthritis (Th 1 cytokine) generally improves during pregnancy, whereas the condition of the patient with SLE may worsen (Th 2 cytokine) (9) .
Whether pregnancy increases SLE activity has been debated for years. In general, SLE fl ares during pregnancy are usually not severe. However, data from the Hopkins' lupus control studies showed an increased risk of SLE nephritis (10) . Lupus nephritis during pregnancy is a clinical challenge. Patients with recent active nephritis are at the highest risk, while those in long-standing remission with no past renal disease are at the lowest risk (11) . Urinary protein excretion normally rises during pregnancy in women with underlying proteinuria, so an increase does not always indicate active disease (11) . Complement levels normally decrease during pregnancy, and this limits their utility as a marker of active lupus.
Pregnant women with SLE are at increased risk for preeclampsia and eclampsia (12, 13) . Among women with renal disease, the incidence of preeclampsia and eclampsia may be as high as 66% (14) . Proteinuria, hypertension, and a decline in renal function can also be seen in preeclampsia; in fact, differentiating between these two conditions is diffi cult, and they can also coexist.
Pregnancy in a patient with SLE is associated with an increased risk of fetal and maternal outcomes, so these patients are at high risk. A multidisciplinary therapeutic approach is required for the treatment of the pregnant patient with SLE. Ideally, management of these patients should start before conception. Th e prognosis of pregnant SLE patients has improved with better diagnosis and treatment. Pregnancy is contraindicated when women have active lupus nephritis. Pregnancy should be avoided until there is a renal remission of at least 6 months' duration. Th e Table lists the contraindications to pregnancy in women with SLE.
In our two cases, SLE was fi rst recognized during pregnancy. Case 2 developed severe SLE nephritis during her pregnancy but also had marked renal improvement at the end of pregnancy. Th ese two cases demonstrate two main points:
• Pregnancy can be associated with the development of fullblown SLE in a previously subclinical patient.
• Severe organ involvement, including SLE nephritis, can be the initial manifestation of lupus during pregnancy.
